{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:07:53Z","timestamp":1794377273389,"version":"4.9.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jhep.2024.12.046","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T11:44:46Z","timestamp":1736423086000},"page":"31-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials"],"prefix":"10.1016","volume":"83","author":[{"given":"Javier","family":"Armisen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Rauschecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4379-5348","authenticated-orcid":false,"given":"Janeli","family":"Sarv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8368-5775","authenticated-orcid":false,"given":"Mathias","family":"Liljeblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9829-3037","authenticated-orcid":false,"given":"Linda","family":"Wernevik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Niazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9839-2433","authenticated-orcid":false,"given":"Jane","family":"Kn\u00f6chel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0886-192X","authenticated-orcid":false,"given":"Olof","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7161-4258","authenticated-orcid":false,"given":"Ther\u00e9se","family":"Sandell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-4369","authenticated-orcid":false,"given":"James","family":"Sherwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4369-2903","authenticated-orcid":false,"given":"Linn\u00e9a","family":"Bergenholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hall\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9930-9929","authenticated-orcid":false,"given":"Maria","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4093-1032","authenticated-orcid":false,"given":"Ingela","family":"Maxvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Bhanot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-9303","authenticated-orcid":false,"given":"Shuling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4234-224X","authenticated-orcid":false,"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2301-2130","authenticated-orcid":false,"given":"Ola","family":"Fjellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4158-8018","authenticated-orcid":false,"given":"Daniel","family":"Lind\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny E.","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-9991","authenticated-orcid":false,"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.12.046_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.046_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.12.046_bib3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4254\/wjh.v9.i11.533","article-title":"Hepatocellular carcinoma in non-alcoholic steatohepatitis: current knowledge and implications for management","volume":"9","author":"Cholankeril","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2024.12.046_bib4","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jhep.2016.07.033","article-title":"NAFLD and liver transplantation: current burden and expected challenges","volume":"65","author":"Pais","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.12.046_bib5","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/hep.26986","article-title":"Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S","volume":"59","author":"Wong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.046_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease \u2013 meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.046_bib7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.12.046_bib8","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/HEP.0000000000000896","article-title":"PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic-associated steatotic liver disease","volume":"80","author":"Chalasani","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.046_bib9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.12.046_bib10","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2024.12.046_bib11","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jhep.2024.12.046_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101111","article-title":"Genetic and epigenetic factors determining NAFLD risk","volume":"50","author":"Jonas","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhep.2024.12.046_bib13","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/apt.15738","article-title":"Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis","volume":"51","author":"Carlsson","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.12.046_bib14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jhep.2023.05.007","article-title":"Therapeutic opportunities for the treatment of NASH with genetically validated targets","volume":"79","author":"Lind\u00e9n","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.12.046_bib15","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2024.12.046_bib16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/hep.23622","article-title":"Homozygosity for the patatin-like phospholipase-3\/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"51","author":"Valenti","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.046_bib17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort","volume":"73","author":"Anstee","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.12.046_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2024.12.046_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.12.046_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/apt.14856","article-title":"Impact of patatin-like phospholipase domain containing 3 rs738409 G\/G genotype on hepatic decompensation and mortality in patients with portal hypertension","volume":"48","author":"Mandorfer","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.12.046_bib21","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hep.31032","article-title":"Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores predict liver disease mortality in the U.S. population","volume":"71","author":"Unalp-Arida","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.046_bib22","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cgh.2019.08.011","article-title":"Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease","volume":"18","author":"Grimaudo","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.12.046_bib23","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/liv.15678","article-title":"The greater impact of PNPLA3 polymorphism on liver-related events in Japanese non-alcoholic fatty liver disease patients: a multicentre cohort study","volume":"43","author":"Seko","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.12.046_bib24","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1074\/jbc.M109.064501","article-title":"A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis","volume":"285","author":"He","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2024.12.046_bib25","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1093\/hmg\/ddu121","article-title":"PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells","volume":"23","author":"Pirazzi","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jhep.2024.12.046_bib26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.27242","article-title":"Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis","volume":"61","author":"Smagris","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.046_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","article-title":"Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice","volume":"22","author":"Lind\u00e9n","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhep.2024.12.046_bib28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/hep.31609","article-title":"Identification of a metabolic, transcriptomic, and molecular signature of patatin-like phospholipase domain containing 3-mediated acceleration of steatohepatitis","volume":"73","author":"Banini","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.046_bib29","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/hep.29273","article-title":"The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation","volume":"66","author":"BasuRay","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.046_bib30","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/hep.30583","article-title":"PNPLA3, CGI-58, and inhibition of hepatic triglyceride hydrolysis in mice","volume":"69","author":"Wang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.046_bib31","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1002\/hep4.2032","article-title":"Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans","volume":"6","author":"Ericson","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2024.12.046_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2022.08.022","article-title":"IL-6\/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease","volume":"78","author":"Park","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.12.046_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe9117","article-title":"An oral antisense oligonucleotide for PCSK9 inhibition","volume":"13","author":"Gennemark","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2024.12.046_bib34","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/nat.2016.0623","article-title":"Disposition and pharmacokinetics of a GalNAc3-conjugated antisense oligonucleotide targeting human lipoprotein (a) in monkeys","volume":"26","author":"Yu","year":"2016","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jhep.2024.12.046_bib35","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1074\/jbc.RA118.002333","article-title":"Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets","volume":"293","author":"Mitsche","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2024.12.046_bib36","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1038\/s41467-024-49224-x","article-title":"PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein","volume":"15","author":"Johnson","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2024.12.046_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15943-z","article-title":"PNPLA3 variant and portal\/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress","volume":"7","author":"Carpino","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2024.12.046_bib38","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1073\/pnas.1901974116","article-title":"Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis","volume":"116","author":"BasuRay","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2024.12.046_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127902","article-title":"Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids","volume":"4","author":"Luukkonen","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhep.2024.12.046_bib40","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJMc2402341","article-title":"Phase 1 trials of PNPLA3 siRNA in I148M homozygous patients with MAFLD","volume":"391","author":"Fabbrini","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2024.12.046_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22116100","article-title":"The propensity of the human liver to form large lipid droplets is associated with PNPLA3 polymorphism, reduced INSIG1 and NPC1L1 expression and increased fibrogenetic capacity","volume":"22","author":"Ferri","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2024.12.046_bib42","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1478-3231.2011.02534.x","article-title":"PNPLA3 rs738409C\/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence","volume":"31","author":"Falleti","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.12.046_bib43","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3417","article-title":"A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis","volume":"47","author":"Buch","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2024.12.046_bib44","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.dld.2012.05.006","article-title":"PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals","volume":"44","author":"Burza","year":"2012","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2024.12.046_bib45","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/hep.26767","article-title":"Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data","volume":"59","author":"Tr\u00e9po","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.046_bib46","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.cmet.2023.10.008","article-title":"The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans","volume":"35","author":"Luukkonen","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2024.12.046_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2020.06.010","article-title":"STAT3: a key regulator in liver fibrosis","volume":"21","author":"Zhao","year":"2021","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2024.12.046_bib48","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gutjnl-2021-324264","article-title":"Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease","volume":"71","author":"Tamaki","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.12.046_bib49","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41588-024-01720-y","article-title":"Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis","volume":"56","author":"Ghouse","year":"2024","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2024.12.046_bib50","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2024.12.046_bib51","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.1021\/acs.jmedchem.6b00551","article-title":"The medicinal chemistry of therapeutic oligonucleotides","volume":"59","author":"Wan","year":"2016","journal-title":"J Med Chem"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T01:04:27Z","timestamp":1766192667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0168827825000030"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.12.046","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.12.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}